Mirum Pharmaceuticals, Inc.
https://mirumpharma.com
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Mirum Pharmaceuticals, Inc.
Dengue Vaccine Qdenga & Nine Drugs Win EMA Thumbs Up
The European Medicines Agency has delivered its verdict on marketing applications for a raft of new medicines.
Albireo Ready To Seek Second Bylvay Indication In Alagille Syndrome
With Bylvay approved last year for progressive familial intrahepatic cholestasis, Albireo looks to add an estimated 25,000 addressable patients to IBAT inhibitor’s label with strong Phase III data in ALGS.
EU Moment of Truth For Abaloparatide & Advanced Therapy Tab-Cel
Radius’s abaloparatide, which was previously rejected by the European Medicine Agency, is among the latest products that are this week being considered for EU-wide marketing approval by the agency.
Mirum Awaits EMA Verdict On ‘Reprioritized’ Livmarli Filing
Mirum could soon find out if its decision to reprioritize its EU filings for its rare liver disease drug has paid off.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Specialty Pharmaceuticals